---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-096765"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2022-04-06T23:59:59+00:00"
generated_at: "2026-06-26T09:11:46.931035+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology advances IK-175 combination cohort to stage two in Phase 1b trial for urothelial carcinoma

## Summary
- IK-175 (AHR antagonist) Phase 1b trial (NCT04200963) combination with nivolumab expansion cohort advanced to stage two in April 2022.
- Patients are advanced/metastatic urothelial carcinoma progressed after multiple prior therapies including checkpoint inhibitors.
- Simon two-stage design requires predefined ORR threshold (RECIST 1.1) to be met in stage one before advancing to stage two.
- Monotherapy expansion cohort had previously advanced to stage two in September 2021.
- Initial clinical data from the trial expected to be submitted to an oncology conference in H2 2022.

## SEC filing metadata
- accession: 0001193125-22-096765
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2022-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312522096765/0001193125-22-096765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312522096765/d311568d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-096765
- JSON: https://secwatch.observer/filing/0001193125-22-096765.json
- Plain text: https://secwatch.observer/filing/0001193125-22-096765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.